A synthetic porcine version of ACTH (SNP-ACTH(1-39) Gel), developed by Cerium Pharmaceuticals, is currently on phase III trial for the treatment of primary membranous nephropathy, an autoimmune disease of the kidneys causing inflammation and damage to the glomeruli filtration function in which MC1 agonism has shown promise.181. The gene discussed is POMC; the disease is membranous glomerulonephritis.